Natural, Proteolytic Release of a Soluble Form of Human IL-15 Receptor α-Chain That Behaves as a Specific, High Affinity IL-15 Antagonist
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
IL-15 and IL-2 are two structurally and functionally related cytokines whose high affinity receptors share the IL-2R β-chain and γ-chain in association with IL-15R α-chain (IL-15Rα) or IL-2R α-chain, respectively. Whereas IL-2 action seems restricted to the adaptative T cells, IL-15 appears to be crucial for the function of the innate immune responses, and the pleiotropic expression of IL-15 and IL-15Rα hints at a much broader role for the IL-15 system in multiple cell types and tissues. In this report, using a highly sensitive radioimmunoassay, we show the existence of a soluble form of human IL-15Rα (sIL-15Rα) that arises from proteolytic shedding of the membrane-anchored receptor. This soluble receptor is spontaneously released from IL-15Rα-expressing human cell lines as well as from IL-15Rα transfected COS-7 cells. This release is strongly induced by PMA and ionomycin, and to a lesser extent by IL-1β and TNF-α. The size of sIL-15Rα (42 kDa), together with the analysis of deletion mutants in the ectodomain of IL-15Rα, indicates the existence of cleavage sites that are proximal to the plasma membrane. Whereas shedding induced by PMA was abrogated by the synthetic matrix metalloproteinases inhibitor GM6001, the spontaneous shedding was not, indicating the occurrence of at least two distinct proteolytic mechanisms. The sIL-15Rα displayed high affinity for IL-15 and behaved as a potent and specific inhibitor of IL-15 binding to the membrane receptor, and of IL-15-induced cell proliferation (IC50 in the range from 3 to 20 pM). These results suggest that IL-15Rα shedding may play important immunoregulatory functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin 15: biology and relevance to human disease
Fehniger, T. A., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.1.14 · Cited by 976 · cited 1×
“Among these disorders are autoimmune diseases, inflammatory diseases, infectious diseases, transplant rejection, cancer, and immunodeficiencies (38).”
Background
Cited by
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Effector and Memory CTL Differentiation
Williams, M. A., & Bevan, M. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141548 · Cited by 949
DIVERSE FUNCTIONS OF IL-2, IL-15, AND IL-7 IN LYMPHOID HOMEOSTASIS
Ma, A., Koka, R., & Burkett, P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090727 · Cited by 829
Interleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Van Lint, P., & Libert, C. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0607338 · Cited by 564
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundConverting IL-15 to a superagonist by binding to soluble IL-15Rα
Rubinstein, M. P., Kovar, M., Purton, J. F., Cho, J.-H., Boyman, O., Surh, C. D., & Sprent, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600240103 · Cited by 416
IL-15/IL-15 receptor biology: A guided tour through an expanding universe
BUDAGIAN, V, BULANOVA, E., PAUS, R., & BULFONEPAUS, S. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.05.001 · Cited by 385
Lutz, C. T., & Quinn, L. S. (2012) · Aging · doi:10.18632/aging.100482 · Cited by 333
Memory T cells: strategies for optimizing tumor immunotherapy
Liu, Q., Sun, Z., & Chen, L. (2020) · Protein & Cell · doi:10.1007/s13238-020-00707-9 · Cited by 326
Mortier, E., Woo, T., Advincula, R., Gozalo, S., & Ma, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071913 · Cited by 316
Self-citationMortier, E., Quéméner, A., Vusio, P., Lorenzen, I., Boublik, Y., Grötzinger, J., Plet, A., & Jacques, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508624200 · Cited by 308
Self-citationInterleukin-15 as a myokine: Mechanistic insight into its effect on skeletal muscle metabolism
Nadeau, L., & Aguer, C. (2019) · Applied Physiology Nutrition and Metabolism · doi:10.1139/apnm-2018-0022 · Cited by 83
The generation and function of soluble apoE receptors in the CNS
Rebeck, G. W., LaDu, M. J., Estus, S., Bu, G., & Weeber, E. J. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-15 · Cited by 66
“IL-15) have shed forms that bind the specific interleukins and block their actions on cells [163-165].”
Metadata
- Authors
- Mortier, E., Bernard, J., Plet, A., & Jacques, Y.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 173
- Issue
- 3
- Pages
- 1681-1688
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2114016178
- Cited by
- 143
- References
- 1
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.